GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Camurus AB (OSTO:CAMX) » Definitions » EV-to-EBITDA

Camurus AB (OSTO:CAMX) EV-to-EBITDA : 38.92 (As of May. 22, 2025)


View and export this data going back to 2015. Start your Free Trial

What is Camurus AB EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Camurus AB's enterprise value is kr28,346 Mil. Camurus AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was kr728 Mil. Therefore, Camurus AB's EV-to-EBITDA for today is 38.92.

The historical rank and industry rank for Camurus AB's EV-to-EBITDA or its related term are showing as below:

OSTO:CAMX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -161.46   Med: -12.68   Max: 41021.92
Current: 38.92

During the past 13 years, the highest EV-to-EBITDA of Camurus AB was 41021.92. The lowest was -161.46. And the median was -12.68.

OSTO:CAMX's EV-to-EBITDA is ranked worse than
84.65% of 495 companies
in the Biotechnology industry
Industry Median: 8.09 vs OSTO:CAMX: 38.92

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2025-05-22), Camurus AB's stock price is kr528.50. Camurus AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was kr9.150. Therefore, Camurus AB's PE Ratio (TTM) for today is 57.76.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


Camurus AB EV-to-EBITDA Historical Data

The historical data trend for Camurus AB's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Camurus AB EV-to-EBITDA Chart

Camurus AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -49.99 -80.66 154.23 50.94 53.61

Camurus AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 46.14 105.68 96.75 53.61 42.23

Competitive Comparison of Camurus AB's EV-to-EBITDA

For the Biotechnology subindustry, Camurus AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Camurus AB's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Camurus AB's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Camurus AB's EV-to-EBITDA falls into.


;
;

Camurus AB EV-to-EBITDA Calculation

Camurus AB's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=28346.148/728.35
=38.92

Camurus AB's current Enterprise Value is kr28,346 Mil.
Camurus AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr728 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Camurus AB  (OSTO:CAMX) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Camurus AB's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=528.50/9.150
=57.76

Camurus AB's share price for today is kr528.50.
Camurus AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr9.150.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


Camurus AB EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Camurus AB's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Camurus AB Business Description

Traded in Other Exchanges
Address
Ideon Science Park, Lund, SWE, SE-223 70
Camurus AB is a research and development-focused pharmaceutical company. It develops pharmaceuticals for the treatment of serious and chronic diseases such as opioid addiction, pain, cancer, and endocrine diseases. The Camurus' clinical pipeline includes products for the treatment of dependence, pain, cancer and endocrine diseases, which are developed in-house and in collaboration with international pharmaceutical companies. The company's product pipeline includes CAM2029, CAM4072 and CAM2043.

Camurus AB Headlines